Subscribe To
Janone to present prior phase ii data on diabetic neuropathy at the ohio society of interventional pain physicians annual meeting
JAN101 Showed statistically Significant Reduction in Pain and Improvement in Nerve Conduction Velocity ...
August 18, 2023, 12:42 pm
Eli lilly reports positive results in trial of tretment for non-small cell lung cancer
Eli Lilly & Co. LLY, -1.17% said Friday a late-stage trial of a treatment for a type of non-small cell lung cancer met its main goal. The Phase 3 tria...
August 4, 2023, 8:01 am
Elevar therapeutics announces publication of phase 3 cares 310 study results in the lancet
In CARES 310, camrelizumab plus rivoceranib demonstrated statistically significant and clinically meani...
July 25, 2023, 1:39 am
Acumen: a first in targeting, may lead to improvement for early ad patients
Positive topline results released from phase 1 INTERCEPT-AD study, which used ACU193 for the treatment of patients with early AD. The global market fo...
July 18, 2023, 8:34 am
Virios therapeutics announces positive data demonstrating improvement in multiple long-covid symptoms following treatment with a combination of valacyclovir and celecoxib in an exploratory, open-label
ATLANTA, July 17, 2023 (GLOBE NEWSWIRE) — Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company fo...
July 17, 2023, 11:05 am
Cassava sciences: why market skepticism persists despite positive findings on simufilam
Cassava Sciences' Alzheimer's drug, simufilam, reduced cognitive decline by 38% in a small study, but the results were not ...
July 5, 2023, 3:05 pm
Genfit shares fall despite positive trial results for rare cholestatic liver disease therapeutic
GENFIT (NASDAQ:GNFT) shares fell 5% after initially rising on positive results from its clinical trial with partner Ipsen for the investigational the...
June 30, 2023, 10:46 am
Bioxcel therapeutics announces positive topline results from tranquility ii phase 3 trial of bxcl501 for acute treatment of alzheimer’s disease-related agitation
Trial met primary endpoint with the 60 mcg dose, with BXCL501 demonstrating a statistically significant...
June 29, 2023, 10:00 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in ...
June 24, 2023, 9:01 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in ...
June 24, 2023, 9:01 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in ...
June 24, 2023, 9:01 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in ...
June 24, 2023, 9:01 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in ...
June 24, 2023, 9:01 am
Data from 89bio’s enliven phase 2b trial of pegozafermin in patients with nonalcoholic steatohepatitis (nash) published in the new england journal of medicine and simultaneously presented in a late-br
– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in ...
June 24, 2023, 9:01 am
Vera therapeutics shares surge on positive igan trial results
Vera Therapeutics, Inc shares climbed 20% to $15.38 on Tuesday after the late-stage biotechnology company revealed positive trial results for atacicep...
June 20, 2023, 3:56 pm
Aldeyra's stellar allergic conjunctivitis results to raise reproxalap monetization value
Aldeyra Therapeutics reported positive results from a Phase III study of Reproxalap, an eye drop drug for allergic conjunctivitis and dry eye disease ...
June 16, 2023, 10:55 am
3 dividend-paying large-cap stocks to buy in june
While going the route of dividend-paying large-cap stocks might not lead to gargantuan returns, you're likely to improve your odds of success. To use ...
June 8, 2023, 6:50 pm
Novocure's lung cancer device extends survival in late-stage study
Novocure said on Tuesday its experimental device to treat a type of lung cancer showed a statistically ...
June 6, 2023, 8:38 am
Astrazeneca (azn) drug combo meets endometrial cancer study goal
AstraZeneca (AZN) reports statistically significant results from a late-stage study evaluating the comb...
May 29, 2023, 8:50 am
Bioxcel therapeutics: serenity iii part 1 didn't meet primary endpoints, part 2 will
BioXcel has just published the results of the first part of the Serenity III trial in which, although clinically good results, it has not been able to...
May 28, 2023, 9:07 pm